02/05/2023
I hope all our friends in the industry have recovered from the festivities of 420! We were fortunate enough to spend 420 attending the hosted in Portland this year. In addition to learning about the latest advancements in cannabinoid and plant therapeutics, a big highlight was learning from Dr. Sue Sisley, a trailblazer in the fight to gain FDA approval for plant and alternative medicines. During her keynote, she shared the bold progress that is being made in her phase 3 clinical trials on MDMA-assisted therapy for severe .
In comparison to status quo pharmacotherapies and psychotherapies, the exciting difference is that "MDMA-assisted therapy is addressing the root cause of trauma, helping people process their difficult memories and heal them without the need for daily medication".
Thank you for the brave and hard work you are doing for our communities. Although the FDA has already designated MDMA-assisted therapy for PTSD as a Breakthrough Therapy, we hope our healthcare systems and institutions can swiftly catch up to meet the desperate need for better options and affordable access to them.
For more info on this particular FDA study, check out MAPS (Multidisciplinary Assoc for Psychedelic Studies) at www.maps.org
